Width: | 250 |
Tradename: | Sulanda |
Atc Prefix: | L01 |
Atc Suffix: | EX24 |
Legal Status: | Rx-only |
Synonyms: | Sulfatinib; HMPL-012 |
Cas Number: | 1308672-74-3 |
Pubchem: | 52920501 |
Chemspiderid: | 57583328 |
Unii: | B2K5L1L8S9 |
Chembl: | 4297190 |
Drugbank: | DB15106 |
Iuphar Ligand: | 9769 |
Iupac Name: | N-[2-(Dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1''H''-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide |
C: | 24 |
H: | 28 |
N: | 6 |
O: | 3 |
S: | 1 |
Stdinchi: | 1S/C24H28N6O3S/c1-17-13-19-15-21(7-8-22(19)27-17)33-23-9-10-25-24(29-23)28-20-6-4-5-18(14-20)16-34(31,32)26-11-12-30(2)3/h4-10,13-15,26-27H,11-12,16H2,1-3H3,(H,25,28,29) |
Stdinchikey: | TTZSNFLLYPYKIL-UHFFFAOYSA-N |
Smiles: | CC1=CC2=C(N1)C=CC(=C2)OC3=NC(=NC=C3)NC4=CC=CC(=C4)CS(=O)(=O)NCCN(C)C |
Surufatinib (trade name Sulanda) is pharmaceutical drug for the treatment of cancer. In China, it is approved for late-stage, well-differentiated, extrapancreatic neuroendocrine tumors.[1]
It is also under investigation for the treatment of other types of solid tumors.[2] [3]
Surufatinib targets fibroblast growth factor receptor 1 (FGFR1).[4]